The UK-US deal eases medicines pricing uncertainty, lifts NICE threshold, and boosts confidence, but UK pharma still needs pricing reform
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.
Every breakthrough in medicine, every new treatment that changes lives, starts with research.
Integrated Evidence Generation Planning (IEGP) is recognised as a strategic necessity for biopharmaceutical organisations.
Craig Eagle, chief medical officer of Guardant Health, discusses blood as a rich source of biomarker development in cancer prognosis.
A new white paper from Lumanity – ‘A New Framework to Engineer Breakthrough Value for Medicines: Value Inflection Points Across the Development Path’.
Amiculum, a global health communications agency, has entered into an exciting strategic collaboration with VuuAI, a GenAI-driven content production automation plat
The Summit is the leading European industry-focused forum dedicated to accelerating the development of messenger RNA (mRNA) medicines
